All lobbying filings

DLA PIPER LLP (US)

Lobbying for CURRAX PHARMACEUTICALS LLC · Specialty pharmaceutical business

Filing 3rd Quarter - Report

3rd Quarter (July 1 - Sep 30) 2025 · Tennessee · House · Senate · $50,000.00 income · posted Oct 20, 2025

Official filing document

Bills named in this filing 2

HR 4231
Treat and Reduce Obesity Act of 2025
S 1973
Treat and Reduce Obesity Act of 2025

Lobbying activity 1

Pharmacy

Legislative and regulatory policies and proposals related to obesity treatment. Drug compounding safety. H.R. 4231/S. 1973, Treat and Reduce Obesity Act of 2025.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.